Interference No. 103,675
were "re-plotted" in 1995 by Ms. D'Andrea (CX 69; 112). According to
the testimony of Dr. Kingston, the "re-plotted" spectra were
"consistent with" the structure proposed by Dr. Chen (CR 121).
In February 1992, the Analytical Department performed mass
spectral analysis on the sample as prepared on page 039 of Dr. Chen's
notebook number 32044 (CR 96; CX 117). In 1996, after Bouchard et
al.'s effective filing date, the MS spectra were "re-plotted" and the
results obtained were "consistent" with Dr. Chen's proposed structure
for the sample. Later in March 1992, the Analytical Department
performed HRMS analysis on the sample as prepared at page 039 of Dr.
Chen's laboratory notebook number 32044 (CR 100; CX 121, 122). In
early February 1992, Dr. Chen submitted a sample along with a compound
submission form to the Compound Control Department to Dr. Fairchild
for antitumor testing (9 milligrams) and to Dr. Mamber for antitumor
testing (1.2 milligrams) (CX 70). Ms. Kissel assigned the sample
Bristol compound number BMS-183821-01 (CX 70). The results of Dr.
Mamber's testing were included in Dr. Farina's summary in April 1992
(CX 72). In March 1992, the compound was tested for in vitro cancer
cell cytotoxicity (CX 204) and the results printed out by Dr.
Fairchild (CX 206). After retesting, Dr. Fairchild concluded that the
compound tested had the ability to kill human cancer cells in vitro
(CR 144). The results were also included in Dr. Farina's April 1992
120
Page: Previous 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 Next
Last modified: November 3, 2007